A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
NCT ID: NCT05361434
Last Updated: 2026-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
311 participants
OBSERVATIONAL
2022-09-26
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
NCT03647878
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
NCT06934057
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219
Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma
NCT03419572
A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK
NCT03696407
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with no prior systemic treatment for aRCC with clear-cell component;
* Physician-initiated decision to treat with cabozantinib and nivolumab in combination (prior to study enrolment), according to Cabometyx® and Opdivo® approved local labels;
Exclusion Criteria
* History of allergy or hypersensitivity to Cabometyx® or Opdivo® components.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU St Pierre & Brugmann
Brussels, , Belgium
Jessa Ziekenhuis
Hasselt, , Belgium
CHU Namur Mont-Godinne
Yvoir, , Belgium
Centre Hospitalier Universitaire (CHU) de Angers
Angers, , France
Hopital de Mercy- CHR Metz Thionville
Ars-Laquenexy, , France
Institut Ste Catherine - Institut du Cancer Avignon Provence
Avignon, , France
Centre Hospitalier Régional Universitaire de Besançon - Jean Minjoz
Besançon, , France
ICONE
Bezannes, , France
Groupe Hospitalier Saint-André (Bordeaux)
Bordeaux, , France
Institut Bergonié
Bordeaux, , France
Centre Hospitalier de Boulogne-sur-mer
Boulogne-sur-Mer, , France
Centre Hospitalier Fleyriat
Bourg-en-Bresse, , France
Centre Finisterien de Radiotherapie et d'Oncologie
Brest, , France
Centre d'Urologie Site Médipole - Centre Catalan d'Urologie
Cabestany, , France
Centre de Lutte Contre le Cancer Jean PERRIN
Clermont-Ferrand, , France
Centre Hospitalier Universitaire de Clermont-Ferrand - Gabriel-Montpied
Clermont-Ferrand, , France
Centre Hospitalier Universitaire (CHU) Henri Mondor
Créteil, , France
Centre Georges François Leclerc
Dijon, , France
Institut de Cancérologie de Bourgogne
Dijon, , France
Centre Hospitalier Annecy Genevois
Épagny, , France
Centre Hospitalier intercommunal Saint Raphaël Frejus
Fréjus, , France
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, , France
Groupe Hospitalier De La Rochelle - Ré - Aunis
La Rochelle, , France
Centre Hospitalier Universitaire Grenoble Alpes
La Tronche, , France
Hôpital Privé Le Bois
Lille, , France
Hopital Privé Jean Mermoz
Lyon, , France
Centre Hospitalier Universitaire (CHU) de Nantes - Hôtel-Dieu
Nantes, , France
Centre Hospitalier Régional D'orléans
Orléans, , France
Centre Hospitalier Tenon
Paris, , France
Hopital Bichat -Claud Bernard
Paris, , France
Hôpital Européen Georges Pompidou (HEGP)
Paris, , France
Hôpital Pitié-Salpétrière
Paris, , France
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, , France
CHU Charles Nicolle
Rouen, , France
Clinique Mathilde Oncologie médicale
Rouen, , France
Centre d'Oncologie de l'Estuaire
Saint-Nazaire, , France
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, , France
Hospital Foch - Oncology Service
Suresnes, , France
Hospital Foch - Urology Service
Suresnes, , France
Centre Hospitalier Régional Universitaire de (CHRU) de Tours - Hôpital Bretonneau
Tours, , France
CH Dentellières
Valenciennes, , France
Institut de Cancérologie de Lorraine Alexis Vautrin
Vandœuvre-lès-Nancy, , France
General Hospital of Athens Alexandra
Athens, , Greece
Henry Dunant Hospital
Athens, , Greece
ATTIKO University Hospital
Chaïdári, , Greece
Papageorgiou General Hosp of Thessaloniki
Thessaloniki, , Greece
Ospedale Generale Provincial
Macerata, , Italy
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", IRCCS - Oncologia
Meldola, , Italy
Fondazione IRCCS, Istituto Nazionale dei Tumori
Milan, , Italy
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Napoli, , Italy
AOU San Luigi Gonzaga
Orbassano, , Italy
IOV - Istituto Oncologico Veneto - IRCCS - Ospedale Busonera
Padua, , Italy
P.O Santa Maria delle Grazie, ASL Napoli 2 Nord
Pozzuoli, , Italy
Ospedale "Santa Maria delle Croci" di Ravenna
Ravenna, , Italy
Ospedale San Camillo Forlanini
Roma, , Italy
Policlinico Universitario Campus Biomedico
Roma, , Italy
PU A.Gemelli, Università Cattolica del Sacro Cuore
Roma, , Italy
Akershus Universitetssykehus
Lørenskog, , Norway
King Abdulaziz Medical City - Jeddah
Jeddah, , Saudi Arabia
King Abdulaziz Medical City- Riyadh
Riyadh, , Saudi Arabia
Chonnam National University Hwasun Hospital
Jeongnam, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul St Mary's Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Belfast City Hospital
Belfast, , United Kingdom
Edinburgh Cancer Centre, Western General Hospital
Edinburgh, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Barthelemy P, Dutailly P, Qvick B, Perrot V, Verzoni E. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma. Future Oncol. 2024 Apr;20(13):811-819. doi: 10.2217/fon-2023-0353. Epub 2023 Jul 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLIN-60000-452
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.